Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC

Sponsor
Jiangsu ShengDiYa Medicine Co., Ltd.
Study ID
NCT02852798
Status
Unknown

Conditions

  • Nonsquamous Nonsmall Cell Neoplasm of Lung

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apatinib Combined With Docetaxel — DRUG
    Docetaxel 75 mg/ (m2.d)IV gtt 1h d1 q3w Apatinib Mesylate Tablets : 500 mg qd, 4 weeks as one cycle for continuous drug administration

Study Details

This is a clinical study of Apatinib Mesylate Tablets combined with docetaxel monotherapy as second-line therapy of advanced EGFR wild-type, non-squamous, non-small-cell lung cancer.

Key Dates

Start date
Aug 31, 2016
Status verified
Aug 2016
Primary completion
Aug 31, 2017
Completion
Aug 31, 2018

Study Design

Enrollment
60 participants (estimated)

Primary Outcome Measure

Progression Free Survival [ Time Frame: 1 year ]

Central Contacts